Macroview Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Macroview Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16	Closed	-$6.51K	–	703
2023 Q4	$6.51K	Buy	+16	New	+$5.91K	0.01%	359
2023 Q3	–	Sell	-2	Closed	-$704	–	868
2023 Q2	$704	Hold	2	–	–	﹤0.01%	438
2023 Q1	$631	Sell	2 -38	-95%	-$11.4K	﹤0.01%	400
2022 Q4	$11.6K	Buy	40 +38	+1,900%	+$11.6K	0.02%	190
2022 Q3	$1K	Hold	2	–	–	﹤0.01%	393
2022 Q2	$1K	Hold	2	–	–	﹤0.01%	425
2022 Q1	$1K	Buy	+2	New	+$475	﹤0.01%	414
2020 Q2	–	Sell	-12	Closed	-$3K	–	407
2020 Q1	$3K	Sell	12 -5	-29%	-$1.15K	0.01%	196
2019 Q4	$4K	Buy	+17	New	+$3.44K	0.01%	214
2014 Q3	–	Sell	-15	Closed	-$1K	–	306
2014 Q2	$1K	Hold	15	–	–	﹤0.01%	179
2014 Q1	$1K	Buy	+15	New	+$1.19K	﹤0.01%	267

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Macroview Investment Management's VRTX Position: Q1 2024 in Review

Macroview Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 16 shares — an estimated $6.51K sold.

Macroview Investment Management first reported a position in VRTX in Q1 2014 and held it in 11 quarters. The position peaked at $11.6K in Q4 2022. 1,496 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Macroview Investment Management reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Macroview Investment Management sold 16 Vertex Pharmaceuticals shares in Q1 2024, an estimated $6.51K.
Macroview Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Macroview Investment Management's Vertex Pharmaceuticals position peaked at $11.6K in Q4 2022.
1,496 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Macroview Investment Management's 13F filing for Q1 2024, filed 30 Apr 2024.